INTRODUCTION
Bone homeostasis is maintained through regulation of the balance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation; an imbalance can lead to the development of diseases such as osteoporosis, periodontal disease, rheumatoid arthritis, multiple myeloma, and metastatic cancers (1). Osteoclasts are multinucleated giant cells that resorb mineralized tissues and are differentiated from hematopoietic stem cells by key factors, such as macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL). In particular, the binding of RANKL to its receptor, RANK, triggers osteoclast differentiation via the activation of mitogen-activated protein (MAP) kinases and transcription factor NF-κB (2). In addition to NF-κB, AP-1 transcription factor member c-Fos and nuclear factor of activated T cells (NFAT) c1 are strongly induced during RANKL-induced osteoclast differentiation and play critical roles in the regulation of genes required for osteoclast differentiation and function. c-Fos is essential for RANKL-mediated induction of NFATc1 (3, 4) , and NFATc1 regulates a number of osteoclast-specific genes, including DC-STAMP, tartrate-resistant acid phosphatase (TRAP), Atp6v0d2, and osteoclast-associated receptor (OSCAR) (5). Reactive oxygen species (ROS), including free radicals and radical-derived/non-radical reactive species, are involved in the control of many cellular functions and play important roles as regulatory mediators in signaling processes (6). Interestingly, the involvement of ROS in osteoclastogenesis has been reported in several studies: an increase in intracellular ROS caused by RANKL was observed in bone marrow-derived monocyte/macrophage precursor cells (BMMs), and ROS (e.g., hydrogen peroxide) have been shown to be associated with enhanced bone resorption (7, 8) . Increased levels of the antioxidant glutathione (GSH), which plays a major role in oxidant defense via an enzymatic coupling reaction, enhance bone resorption activity (9). In contrast, GSH depletion by L-buthionine-(S,R)-sulfoximine (BSO), a specific inhibitor of GSH synthesis, inhibits osteoclastogenesis and bone pit formation by blocking nuclear importation of NF-κB and AP-1 in RANKL-mediated signaling in RAW 264.7 cells (10). Furthermore, antioxidant enzymes regulating ROS have been shown to http://bmbreports.org Fig. 1 . Glrx2b is up-regulated during RANKL-induced osteoclastogenesis. Bone marrow macrophages (BMMs) were cultured for 3 days with M-CSF (30 ng/ml) and stimulated with RANKL (100 ng/ml) for the indicated times. The cell lysates were analyzed by Western blot. (A) BMMs were transduced with pMX-puro (control) or pMX-puroGlrx2b-c-myc (Glrx2b), selected with puromycin (2 mg/ml) for 2 days, and cultured for 4 days with RANKL (0, 25, 50, 100 ng/ml) in the presence of M-CSF (30 ng/ml). Cells were fixed in 3.7% formalin, permeabilized with 0.1% Triton X-100, and stained with TRAP solution. Mature TRAP-positive multinucleated osteoclasts (MNCs) were photographed under a light microscope (Magnification ×100). (B) TRAP-positive MNCs (nuclear number ＞ 3), (C) TRAP-positive MNCs (nuclear number ＞ 10), and (D) TRAP activity in osteoclasts generated from control BMMs (black column) or BMMs over-expressing Glrx2b (white column) were counted and measured. *P ＜ 0.05, **P ＜ 0.01. (E) BMMs transduced with the control or Glrx2b retrovirus were co-cultured with primary osteoblasts for 6 days and then fixed and stained for TRAP (Magnification ×100). (F) TRAP-positive MNCs (nuclear number ＞ 3) were counted. *P ＜ 0.05, **P ＜ 0.01. (G) Mature osteoclasts derived from transduced BMMs were cultured on carbonate apatite-coated plates for 4 days. Cells were removed and photographed under a light microscope. (H) The bone resorption area was quantified using the Image Pro-plus program, version 4.0. *P ＜ 0.05, **P ＜ 0.01. be closely associated with RANKL-mediated osteoclast differentiation; thioredoxin-1 (Trx1) increases osteoclast formation through the AP-1 and NF-κB signaling pathways in RAW 264.7 cells, but other antioxidant enzymes, specifically glutathione peroxidase-1 (Gpx) and peroxiredoxin-1 (Prx), inhibit RANKL-medicated osteoclastogenesis (11). These results indicate the involvement of ROS and antioxidant enzymes in osteoclastogenesis. The antioxidant protein glutaredoxin (Glrx) catalyzes deglutathionylation of protein-glutathione mixed disulfides (protein-SSG) and plays important roles in redox homeostasis and signal transduction (12). Among Glrx family members, Glrx2 has been shown to play a central role in the regulation of apoptosis. In a functional study, Glrx2 decreased apoptosis induced by doxorubicin and the antimetabolite 2-deoxy-D-glucose by sustaining mitochondrial redox homeostasis (13), but its down-regulation induced sensitivity to phenylarsine oxide and the anticancer agent doxorubicin in HeLa cells (14) . However, to date, no investigation has addressed the potential role of Glrx2 in osteoclastogenesis. Therefore, we investigated the functional involvement of Glrx2 in RANKL-induced osteoclastogenesis in BMMs. Mouse Glrx2 is localized in the mitochondria and has mRNA variants encoding two distinct proteins: mitochondrial isoform a, Glrx2a (UniProt ID: A2A5W4), and non-mitochondrial isoform b, Glrx2b (UniProt ID: Q3UQ95) (15). Because we found that Glrx2b, but not Glrx2a, is strongly induced during RANKL-mediated osteoclast differentiation, we focused on evaluating the functional role of Glrx2b in osteoclastogenesis.
RESULTS

Glrx2b is time-dependently induced during RANKL-mediated osteoclastogenesis
To investigate the expression pattern of Glrx2b in RANKL-mediated osteoclastogenesis, Western blot analysis was performed using BMMs that were differentiated into osteoclasts by treatment with RANKL in the presence of M-CSF. Interestingly, Glrx2b protein was time-dependently induced by RANKL (Fig.  1) . RANKL-mediated osteoclastogenesis was confirmed by evaluating the expression of transcription factors c-Fos and NFATc1, which play major roles in the regulation of osteoclastogenesisrelated genes. RANKL-induced expression of Glrx2b was also confirmed in a RAW264.7 cell-based model of osteoclast differentiation (data not shown).
Over-expression of Glrx2b enhances RANKL-induced osteoclastogenesis
When BMMs were transduced with Glrx2b retrovirus, selected with puromycin, and cultured with M-CSF and RANKL, more mature TRAP-positive multinucleated osteoclasts (MNCs) were formed compared to the control (Fig. 2A) . The number of TRAP-positive MNCs and RANKL-mediated TRAP activity were increased by over-expression of Glrx2b (Fig. 2B-D) . Because RANKL is expressed mainly as a membrane-bound form on osteoblasts and triggers the signaling essential for osteoclast differentiation (4, 16), the effect of endogenous RANKL generated by osteoblasts on Glrx2b-induced osteoclastogenesis
